World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
87
Citations
25264
World Ranking
1217
National Ranking
42

Medicine

D-Index
87
Citations
25292
World Ranking
13736
National Ranking
453

Phillip K. Darcy publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Phillip K. Darcy sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 359 publications — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Phillip K. Darcy D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Phillip K. Darcy sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 87 D-Index — 76th percentile

76% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Phillip K. Darcy is affiliated with the Peter MacCallum Cancer Centre in Australia. Their primary fields of study are Medicine and Immunology and Microbiology, with significant contributions across related subfields such as Oncology, Immunology, Molecular Biology, Genetics, and Pulmonary and Respiratory Medicine.

The main topics covered in their research include:

  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Cancer Immunotherapy and Biomarkers
  • Immunotherapy and Immune Responses
  • Viral Infectious Diseases and Gene Expression in Insects
  • Immune cells in cancer
  • CRISPR and Genetic Engineering

Their publication record includes notable papers such as:

  • "Cellular networks controlling T cell persistence in adoptive cell therapy" (2021) published in Nature Reviews. Immunology
  • "Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity" (2020) published in Nature Immunology
  • "CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy" (2021) published in Nature Communications
  • "Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer" (2023) published in Cancer Cell
  • "FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy" (2024) published in Nature

The venues where Phillip K. Darcy has frequently published include:

  • Regular and Young Investigator Award Abstracts
  • Nature Communications
  • Cytotherapy
  • Cancer Cell
  • Journal of Clinical Oncology

Frequent collaborators in their research include:

  • Paul J. Neeson
  • Paul A. Beavis
  • Kevin Sek
  • Joseph A. Trapani
  • Imran G. House

Phillip K. Darcy's work spans multidisciplinary areas involving cellular therapies, immunotherapy mechanisms, and genetic engineering approaches such as CRISPR. Their research on CAR-T cell therapies is especially prominent, reflecting sustained interest in enhancing immune system function to target cancer effectively.

Best Publications

  • Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis

    Peter Savas;Balaji Virassamy;Chengzhong Ye;Agus Salim;Agus Salim

  • Clinical relevance of host immunity in breast cancer: from TILs to the clinic

    Peter Savas;Roberto Salgado;Carsten Denkert;Christos Sotiriou

  • CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity

    Marian L Burr;Marian L Burr;Marian L Burr;Christina E Sparbier;Yih-Chih Chan;James C Williamson

  • Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells

    Liza B John;Christel Devaud;Connie P M Duong;Carmen S M Yong

  • Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.

    Imran G House;Imran G House;Peter Savas;Peter Savas;Junyun Lai;Junyun Lai;Amanda X. Y. Chen;Amanda X. Y. Chen

  • Gene-engineered T cells for cancer therapy

    Michael H Kershaw;Jennifer A Westwood;Phillip K Darcy;Phillip K Darcy

  • Activating and inhibitory receptors of natural killer cells.

    Hollie J Pegram;Daniel M Andrews;Mark J Smyth;Phillip K Darcy

  • RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors

    Sherene Loi;Sherene Loi;Sathana Dushyanthen;Paul A. Beavis;Roberto Salgado

  • Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape.

    Leisha A. Emens;Paolo A. Ascierto;Phillip K. Darcy;Sandra Demaria

  • CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

    Sherene Loi;Sandra Pommey;Benjamin Haibe-Kains;Paul A Beavis

  • Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.

    David S. Ritchie;Paul J. Neeson;Paul J. Neeson;Amit Khot;Stefan Peinert

  • Induction of tumor-specific T cell memory by NK cell-mediated tumor rejection.

    Janice M Kelly;Phillip K Darcy;Jessica L Markby;Dale I Godfrey

  • Trafficking of T Cells into Tumors

    Clare Y. Slaney;Clare Y. Slaney;Michael H. Kershaw;Phillip K. Darcy

  • CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis

    John Stagg;Upulie Divisekera;Helene Duret;Tim Sparwasser

  • CD73: a potent suppressor of antitumor immune responses

    Paul. A. Beavis;John Stagg;Phillip K. Darcy;Phillip K. Darcy;Mark J. Smyth;Mark J. Smyth

  • Tumor immune evasion arises through loss of TNF sensitivity

    Conor J. Kearney;Conor J. Kearney;Stephin J. Vervoort;Stephin J. Vervoort;Simon J. Hogg;Simon J. Hogg;Kelly M. Ramsbottom

  • Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors

    Paul A. Beavis;Upulie Divisekera;Upulie Divisekera;Christophe Paget;Christophe Paget;Melvyn T. Chow;Melvyn T. Chow

  • Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity.

    A J Davenport;R S Cross;R S Cross;K A Watson;Y Liao

  • Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.

    Emma Nolan;Emma Nolan;Peter Savas;Peter Savas;Antonia N. Policheni;Antonia N. Policheni;Phillip K. Darcy;Phillip K. Darcy

  • Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses

    Paul A. Beavis;Paul A. Beavis;Nicole Milenkovski;Nicole Milenkovski;Melissa A. Henderson;Melissa A. Henderson;Liza B. John;Liza B. John

  • A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and immunological synapse formation.

    Mandy J. Ludford-Menting;Jane Oliaro;Faruk Sacirbegovic;Eric T.-Y. Cheah

  • Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy

    Paul A. Beavis;Paul A. Beavis;Melissa A. Henderson;Melissa A. Henderson;Lauren Giuffrida;Lauren Giuffrida;Jane K. Mills;Jane K. Mills

Frequent Co-Authors

Michael H. Kershaw
Michael H. Kershaw Peter MacCallum Cancer Centre
Mark J. Smyth
Mark J. Smyth QIMR Berghofer Medical Research Institute
Paul A. Beavis
Paul A. Beavis Peter MacCallum Cancer Centre
Joseph A. Trapani
Joseph A. Trapani Peter MacCallum Cancer Centre
Sherene Loi
Sherene Loi Peter MacCallum Cancer Centre
Robert G. Ramsay
Robert G. Ramsay Peter MacCallum Cancer Centre
Michele W. L. Teng
Michele W. L. Teng QIMR Berghofer Medical Research Institute
Ricky W. Johnstone
Ricky W. Johnstone Peter MacCallum Cancer Centre
David Ritchie
David Ritchie Peter MacCallum Cancer Centre
Ilia Voskoboinik
Ilia Voskoboinik Peter MacCallum Cancer Centre

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in expanding their expertise beyond Immunology, pursuing a career in nursing offers diverse opportunities, especially through specialized programs. Transitioning into roles like an acute care nurse practitioner is a popular pathway, with several acute care nurse practitioner programs designed to build advanced clinical skills.

Many students find value in accelerated pathways that expedite their journey into healthcare professions. Online options, such as the accelerated nurse practitioner program, provide flexible learning formats ideal for those looking to shift careers quickly.

For individuals without a nursing background, several options exist to enter the field efficiently. Programs like online accelerated nursing programs for non nurses offer tailored curricula to build foundational knowledge while accelerating degree completion.

Furthermore, some students prioritize accessibility and ease of admission. Exploring the easiest accelerated nursing programs can help identify institutions that match these criteria without compromising educational quality.

Best Scientists Citing Phillip K. Darcy

Trending Scientists

Recently Published Articles